Newer drug therapies have expanded the scope of treatment for patients with JSpA. bDMARDs such as adalimumab, etanercept, infliximab, and secukinumab have demonstrated clinically significant treatment efficacy in ERA and JPsA. Based on extrapolation studies, intravenous golimumab, etanercept, abatacept, and ustekinumab have gained Food and Drug Administration (FDA) approval for JPsA. Long-term follow-up studies continue to demonstrate acceptable safety profiles. There is need for more real-world data on drug efficacy from Registry studies and research on effective de-escalation strategies.
Keyphrases
- ankylosing spondylitis
- rheumatoid arthritis
- drug administration
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- disease activity
- case control
- ulcerative colitis
- adverse drug
- big data
- clinical trial
- open label
- combination therapy
- bone marrow
- machine learning
- systemic lupus erythematosus
- smoking cessation
- artificial intelligence
- replacement therapy